EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial

Joelle Helou, Rachel Glicksman, Andrea Bezjak, Srinivas Raman, Eric Chen, Peter Chung, Laura A Dawson, Andrew Hope, Ali Hosni, Joanna Javor, Patricia Lindsay, Michael Yan und 3 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.12.070 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Joelle Helou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Division of Radiation Oncology, Western University, London, Ontario, Canada; Verspeeten Family Cancer Centre, London Health S…. Hauptthemen laut MEDLINE: Quality of Life, Radiosurgery, Breast Neoplasms, Gastrointestinal Neoplasms. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Princess Margaret Cancer Foundation, Materials and Energy Research Center, Peter Munk Cardiac Centre, University Health Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to report changes in patient-reported health-related quality of life (HRQoL) from a phase II trial evaluating stereotactic body radiation therapy (SBRT) for oligoprogressive (OP) tumors. The study hypothesis was that SBRT would not be associated with a deterioration in HRQoL. METHODS AND MATERIALS: This single-arm, phase II prospective study enrolled patients with metastatic genitourinary (GU), breast, or gastrointestinal (GI) cancers with radiographic OP disease in fewer than 5 sites. All OP sites were treated with SBRT while patients continued their existing systemic therapy. HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline, during radiation therapy, and at 6 weeks, 3 months, and 6 months post-SBRT. A minimally clinically important difference (MCID) was defined as a change >10 points . The primary endpoints were the changes in global health status (GHS) and the QLQ-C30 summary score at 6 months. Secondary endpoints included longitudinal GHS assessment over time. RESULTS: Seventy patients were enrolled (32 GU, 23 breast, and 15 GI). At 6 months, any-site progression occurred in 56% of GU, 48% of breast, and 87% of GI patients. For the entire cohort, mean GHS and QLQ-C30 summary scores declined by 7 and 5 points, respectively (P = .02 and P = .03) neither reaching the MCID. Patients with GU cancer had no significant GHS change (P = .99), whereas patients with breast cancer experienced a statistically significant but nonmeaningful decline (P = .01). Patients with GI cancer had a statistically significant decline that reached the MCID, indicating a clinically meaningful deterioration (P = .007). Progression was an independent predictor of worse GHS at 6 months (P = .003). Among patients without progression, 83% maintained or improved GHS and 91% maintained or improved QLQ-C30 scores. CONCLUSIONS: SBRT for OP tumors is well tolerated. HRQoL declines were primarily driven by disease progression and were clinically meaningful in patients with GI. Patients without progression maintained stable HRQoL following SBRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeRadiosurgeryBreast NeoplasmsGastrointestinal NeoplasmsHumansProspective StudiesFemaleAgedMiddle AgedMaleDisease ProgressionAged, 80 and overPatient Reported Outcome MeasuresHealth Status

Autor:innen und Institutionen

  • Department of Oncology, Division of Radiation Oncology, Western University, London, Ontario, Canada; Verspeeten Family Cancer Centre, London Health Sciences Centre, London, Ontario, Canada. Electronic address: Joelle.he…
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, BC Cancer, Vancouver, Canada; Department of Surgery, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Medical Oncology, Princess Margaret Cancer Centre, University Health, Network, Toronto, Ontario, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.

Förderung

  • Princess Margaret Cancer Foundation
  • Materials and Energy Research Center
  • Peter Munk Cardiac Centre, University Health Network

Zitieren

APA

Helou, J., Glicksman, R., Bezjak, A., Raman, S., Chen, E., Chung, P., Dawson, L. A., Hope, A., Hosni, A., Javor, J., Lindsay, P., Yan, M., Wong, R., Ye, X. Y., & Barry, A. (2026). Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.12.070

Vancouver

Helou J, Glicksman R, Bezjak A, Raman S, Chen E, Chung P, et al. Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.12.070

BibTeX
@article{Helou2026,
  author = {Helou, Joelle and Glicksman, Rachel and Bezjak, Andrea and Raman, Srinivas and Chen, Eric and Chung, Peter and Dawson, Laura A and Hope, Andrew and Hosni, Ali and Javor, Joanna and Lindsay, Patricia and Yan, Michael and Wong, Rebecca and Ye, Xiang Y and Barry, Aisling},
  title = {Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.12.070}
}
Kostenlos starten →